Merck & Co.
Dr. Mayur Ladumor is currently a Senior Scientist in the Department of Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB) at Merck & Co., Inc., West Point, PA, USA. He received his Master's and Ph.D. degrees in Pharmaceutical Sciences from the National Institute of Pharmaceutical Education and Research (NIPER), Punjab, India. He completed his post-doctoral research at the University of Washington, Seattle, WA, USA, before joining Merck. With expertise in model-informed drug development, Dr. Ladumor has developed and applied model-based approaches to support preclinical and clinical programs. His work includes predicting pharmacokinetics (PK) and pharmacodynamics (PD), assessing PK variability across specific populations and pharmacogenomic contexts, evaluating drug-drug interactions and biopharmaceutical applications, and supporting regulatory queries.
He has authored more than 20 peer-reviewed research papers and presented his work at numerous national and international conferences. Dr. Ladumor is the upcoming Vice Chair of the ASCPT Development, Regulatory & Outcomes (DRO) Network and is a member of the Steering Committee of the ACCP Early-Stage Professionals (ESP). He has also served as the Chair of the ASCPT Specific Populations (SPO) Community. Additionally, he is a co-editor of a book on physiologically based PK (PBPK) modeling in drug development, served as a guest editor for a special issue of the journal Metabolites, and was a 2023 Editorial Fellow for the Journal of Pharmacology and Experimental Therapeutics.